--- title: What's New in Neurovascular? News to Know Before SNIS 2026 description: "Meet with SmartTRAK at the Society of Interventional Surgery (SNIS) 23rd Annual Meeting at the Seattle Convention Center ... #neurovascular #neurotherapy #snis2026" --- [Medical Device and Wound Care News and Analysis Blog ](https://blog.smarttrak.com) # [What's New in Neurovascular? News to Know Before SNIS 2026](https://blog.smarttrak.com/snis-2026-know-before-you-go) Written by [Thomas Wallick](https://blog.smarttrak.com/author/thomas-wallick) | 7/15/26 8:03 PM *SmartTRAK *will be attending the Society of Neurointerventional Surgery (SNIS) 23rd Annual Meeting at the Seattle Convention Center. To get you up to speed before the meeting, *SmartTRAK *has put together highlights of recent Neurovascular news. Below is just a small sampling of recent Neurovascular-related news and updates from around the world, compiled, reviewed and posted in real time every day by the expert analysts at *SmartTRAK*. *SmartTRAK* will be attending SNIS 2026 from July 20-24. If you'd like to meet with us in person, please reach out to Anne Staylor, *SmartTRAK*’s Executive Editor and VP & GM, Neuro Therapies, at the show, just click the button below. **Market Updates:** - Kaneka Shows Clear Intent in US Neurovascular Market* SmartTRAK* [notes](https://www.linkedin.com/posts/kanekaneuro-usa_kanekanv-activity-7458504753040408577-fiXt?utm_source=share&utm_medium=member_desktop&rcm=ACoAAAEhal4BIxxKwpvzVZ-EVWSF5bHSfSzAbyY) that Kaneka NV is now training US physicians on a portfolio that combines its own i-ED coils and SurfRider 13 Microcatheter with products from two distribution agreements, WaveSelect and Toro 88, signaling a more intentional move into neurovascular. *LinkedIn* - US Mechanical Thrombectomy Remains Underpenetrated The US MT Market remains significantly underpenetrated and with fewer DMVO procedures, market penetration is slowing. In 2025, only ~30% of eligible AIS patients received MT therapy, increasing to 35% of eligible AIS pts receiving MT therapy by 2030E. *SmartTRAK *US MT Market Overview - US Mechanical Thrombectomy Procedural Mix * SmartTRAK *estimates the US MT procedural mix in 2025 was 65% Aspiration, 3% Stent Retriever (SR) only and 32% Combined technique. *SmartTRAK *US MT Market Overview - US Mechanical Thrombectomy Device Use in 2025 Across all MT techniques (ADAPT, Combined, SR only and Bailout), the total no. of Aspiration devices used in 2025 was down -2.0% YoY, and the total no. of SR devices used was down -22% YoY. *SmartTRAK *US MT Market Overview - US Mechanical Thrombectomy - RCTs Will Help Drive Growth Although MT DMVO procedures have slowed and the market is focused on “precision thrombectomy,” RCTs demonstrating the effectiveness of MT in other patient populations (low ASPECTS, lg core strokes, late time window) will help drive growth in the next 5 years. [**](https://app.smarttrak.com/markets/qs/a47536c6vde33f79ac10024fcbfa8b28) - US Mechanical Thrombectomy - 2nd-Gen  RCTs and DMVO Rebound The 2nd-gen studies underway to determine which pt subgroups and brain territories are most likely to benefit from DMVO MT procedures may provide the evidence needed to support a rebound in DMVO procedures over the next 5 years. [**](https://app.smarttrak.com/markets/qs/a47536c6vde33f79ac10024fcbfa8b28) **Clinical/Regulatory:** - **Penumbra** Penumbra [announced](https://www.prnewswire.com/news-releases/penumbras-thunderbolt-receives-fda-clearance---bringing-computer-assisted-vacuum-thrombectomy-technology-to-stroke-302798514.html) that THUNDERBOLT received FDA clearance as the first computer‑assisted vacuum thrombectomy (CAVT) device for acute ischemic stroke, offering modulated aspiration to improve speed and completeness of clot removal and potentially transform stroke treatment. - **Toro**** Neurovascular **Toro Neurovascular [announced](https://www.globenewswire.com/news-release/2026/03/11/3253906/0/en/Toro-Neurovascular-Announces-FDA-510-k-Clearance-for-Toro-88-Superbore-Catheter.html) that its Toro 88 Superbore Catheter has received FDA 510(k) clearance and the first clinical cases have been successfully completed. Kaneka Medical is leading the US launch of Toro 88. - **Serenity Shepard Stent Receives BDD for Pulsatile Tinnitus **Serenity Medical [announced](https://www.globenewswire.com/news-release/2026/06/30/3319916/0/en/Serenity-Medical-Receives-U-S-FDA-Breakthrough-Device-Designation-for-The-Serenity-Shepherd-Stent-System-to-Treat-Pulsatile-Tinnitus.html) it received FDA Breakthrough Device Designation for its Serenity Shepard Stent System for the treatmen of severe pulsatile tinnitus. This follows the March 2026 HDE [approval](https://serenity-medical.com/news/serenity-medical-receives-u-s-fda-hde-approval-of-the-river-stent-the-first-venous-stent-approved-for-severe-refractory-idiopathic-intracranial-hypertension-iih/) of Serenity’s River Stent for the treatment of refractory idiopathic intracranial hypertension. - **Sentante Secures CE Mark for Endovascular Robot **Sentante [announced](https://sentante.com/news/sentante-receives-ce-mark-approval-unlocking-commercialisation-of-its-endovascular-robotic-platform/) it has received CE Mark for its endovascular robot. The company will now begin its initial rollout, clinical training and commercial expansion. The robot has received FDA Breakthrough Device Designation and is in the Total Product Life Cycle Advisory Program. - Balt USA Balt USA [received](https://www.accessdata.fda.gov/cdrh_docs/pdf25/K254223.pdf) FDA 510(k) clearance for its Next Generation 088 Catheter on 4/16/26 for use in neuro, peripheral and coronary vasculatures. The guidewire will be packaged with a dilator, introducer sheath, 9F rotating hemostasis valve and 8F hemostasis valve adaptor. **Patents:** - Route 92 Route 92 Medical was [issued](https://ppubs.uspto.gov/pubwebapp/external.html?q=(12521523).pn.&db=USPAT&type=ids) US Patent "Catheter Systems For Applying Effective Suction In Remote Vessels And Thrombectomy Procedures Facilitated By Catheter Systems" describing a suction catheter with extendable nozzle that deploys and forms a sealed aspiration lumen. *12521523** * - Perfuze Perfuze's US Patent Application "High Flexibility, Kink Resistant Catheter Shaft" was [published](https://ppubs.uspto.gov/pubwebapp/external.html?q=(20260151593).pn.&db=US-PGPUB&type=ids) [describing](https://ppubs.uspto.gov/pubwebapp/external.html?q=(20260151592).pn.&db=US-PGPUB&type=ids) a flexible, kink-resistant catheter with a corrugated distal shaft and helical reinforcement that enhances navigation through tortuous vessels. *20260151593* - **JNJ MedTech **Neuravi's US Patent Application "Clot Retrieval System For Removing Occlusive Clot From A Blood Vessel" was [published](https://ppubs.uspto.gov/pubwebapp/external.html?q=(20260144558).pn.&db=US-PGPUB&type=ids) describing an MT device with a flared distal barrel section and asymmetrical strut design to create varied radial force to improve clot engagement. *20260144558* - **Medtronic** Covidien was [granted](https://ppubs.uspto.gov/pubwebapp/external.html?q=(12648783).pn.&db=USPAT&type=ids) US Patent "Aspiration Systems And Methods And Expanding-mouth Catheters" describing an aspiration catheter with a radially expandable distal mouth that engages clot and cyclically expands/contracts at a controlled frequency to enhance clot capture. *12648783* - **Terumo Neuro** MicroVention was [issued](https://ppubs.uspto.gov/pubwebapp/external.html?q=(12616820).pn.&db=USPAT&type=ids) US Patent "Reinforced Balloon Catheter" describing a neurovascular balloon catheter system with a gas-permeable purge port and de-airing channel that vents trapped gas while blocking liquid passage during balloon inflation. *12616820* **Deals/Financing: ** - **Penumbra** For Q126, PEN noted that the company remains focused on its pending acquisition by Boston Scientific Corporation, which is expected to close in 2026. [*PEN Q126 Earnings Release*](https://www.penumbrainc.com/penumbra-inc-reports-first-quarter-2026-financial-results/) - **Medtronic** Medtronic [completed](https://www.prnewswire.com/news-releases/medtronic-completes-acquisition-of-scientia-vascular-seamlessly-integrating-access-and-therapeutic-portfolios-for-neurovascular-care-302798654.html) its acquisition of Scientia Vascular, valued at $550MM with potential additional earn-out and milestone payments post-acquisition. Scientia’s access product lines complement the MDT neurovascular portfolio for a full procedural workflow. - **Route 92** Route 92 Medical [announced](https://www.globenewswire.com/news-release/2026/04/07/3269028/0/en/Route-92-Medical-Announces-50-Million-Growth-Financing.html) $50MM in growth financing led by Novo Holdings joined by new investor Sectoral Asset Mgmt and returning investors. Proceeds will help accelerate global commercial expansion, advance clinical evidence and continue product innovation across the platform. - **Imperative Care** Imperative Care [closed](https://www.businesswire.com/news/home/20260317692252/en/Imperative-Care-Announces-%24100-Million-Financing) an oversubscribed $100MM financing round with both new and existing investors participating. Proceeds will support the commercialization of existing thrombectomy products, the development of the Telos robotic platform and clinical evidence generation. - **First Neurovascular Robotic Technology Acquisition of 2026 **Stereotaxis will [acquire](https://www.globenewswire.com/news-release/2026/04/15/3274290/21634/en/Stereotaxis-Announces-Definitive-Agreement-to-Acquire-Robocath.html) Robocath, currently selling the R-One+ robotic system for interventional cardiology and developing a system for neurointervention. The transaction, expected to close in mid-2026, includes a $20MM upfront payment and $25MM contingent on milestones. - **CereVasc Closes $85MM Series C **CereVasc [closed](https://www.prnewswire.com/news-releases/cerevasc-inc-announces-over-subscribed-85-million-series-c-financing-to-advance-its-novel-eshunt-system-for-the-treatment-of-normal-pressure-hydrocephalus-302791507.html) an $85MM Series C financing round with both Johnson & Johnson Innovation (JJDC) and Medtronic as participating investors. Funds will be used to advance clinical and regulatory pathways for its eShunt minimally invasive treatment for Normal Pressure Hydrocephalus. **Studies:** - **Monopoint – Route 92** A meta-analysis of 7 studies (490 LVO pts) [found](https://link.springer.com/article/10.1007/s10143-026-04376-w) the 0.088-inch HiPoint Reperfusion System increased first-pass effect (+18%) and near-complete reperfusion (+23%) vs other techniques, with 3% sICH, 94% reperfusion and significant NIHSS improvement. *Neurosurg Rev* - Penumbra Penumbra announced that it has [initiated](https://www.penumbrainc.com/first-patient-enrolled-in-penumbras-forward-study-evaluating-mechanical-thrombectomy-and-computer-assisted-vacuum-thrombectomy-for-distal-acute-ischemic-stroke/) the FORWARD Study to evaluate mechanical thrombectomy and CAVT with its RED catheters and THUNDERBOLT in distal M2 occlusions. The first of 250 patients worldwide was enrolled by Dr. Keith Woodward in Knoxville, TN. - Combined SR + Aspiration Improves Recanalization, Not Outcomes A pooled analysis of the ASTER, ASTER2 and VECTOR RCTs [found](https://academic.oup.com/esj/article/11/7/aakag077/8725542) first-line combined stent retriever + aspiration achieved higher successful reperfusion without rescue therapy than aspiration or SR alone, but did not improve 90-day functional outcomes, NIHSS or safety. *Eur Stroke J* - Study Shows IVT Before MT Yields Higher Recanalization Rates A target trial emulation (N=347) evaluating the safety of omitting thrombolysis in extended windows [found](https://pubmed.ncbi.nlm.nih.gov/42387846/) direct MT is not non-inferior to IVT+MT beyond 4.5 hours or at wake-up. The study concluded IVT before MT yields significantly higher successful recanalization rates. *EJN* - **ZOOM**** - ****Imperative Care** Imperative Care is [sponsoring](https://clinicaltrials.gov/study/NCT07491952?tab=study) a 750-patient study evaluating ADAPT 2.0 first-line aspiration thrombectomy with its Zoom System with Continuous Dual Aspiration (CDAT) for AIS pts. Estimated start is March 2026. *clinicaltrials.gov* Want to learn more about *SmartTRAK*’s Neuro Therapies coverage, including up-to-date intelligence on neuro therapy industry trends, news, financial data and competitor developments, just click the button below. ***[SmartTRAK](https://www.smarttrak.com/)** *is the Medtech industry’s only global Insights-as-a-Service solution for the Orthopedics, Wound Care, Regenerative Medicine and Neuro Therapy markets. SmartTRAK’s proprietary methodology turns disparate data from hundreds of sources into powerful insights customers can rely on as the trusted source for strategic decision-making. The *SmartTRAK *enterprise platform includes rich daily updates, comprehensive market coverage and simple-to-use tools and dashboards for market, product and financial analysis. Customers leveraging the *SmartTRAK *platform also have direct access to market experts for inquiries and advisory services. If you would like a demo of what *SmartTRAK *offers and how we can help increase proficiency, improve productivity and reduce costs for your company, just click [here](https://www.smarttrak.com/contact-us).  [View full post](https://blog.smarttrak.com/snis-2026-know-before-you-go) ```json { "@context" : "http://schema.org", "@type" : "BlogPosting", "author" : { "@type" : "Person", "name" : "Thomas Wallick" }, "dateModified" : "2026-07-15T20:03:56.791Z", "datePublished" : "2026-07-15T20:03:56Z", "headline" : "What's New in Neurovascular? News to Know Before SNIS 2026", "image" : { "@type" : "ImageObject", "height" : 512, "url" : "https://3044256.fs1.hubspotusercontent-na1.net/hubfs/3044256/SNIS%202026%20Seattle%20copy.jpg", "width" : 1024 }, "mainEntityOfPage" : "https://blog.smarttrak.com/snis-2026-know-before-you-go", "publisher" : { "@type" : "Organization", "logo" : { "@type" : "ImageObject", "height" : 60.0, "url" : "https://cdn2.hubspot.net/hubfs/3044256/SmartTRAK%202.0%20Logo%20Art/SmartTRAK%20Logo%20Email250.png", "width" : 187.5 }, "name" : "SmartTRAK Life Sciences News and Analysis Blog" } } ```